Abstract
PD-1 antibody therapy has revolutionised the landscape of metastatic melanoma treatments and outcomes. The aim of our study is to investigate whether immune related adverse events (irAEs) or granulomatous/reactive nodal changes visible on 18F-FDG-PET during treatment with PD-1 antibody therapy for metastatic melanoma predicts improved overall survival.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
